ABVC BioPharma (ABVC) AI Stock Analysis

• Market Cap: $33.58M
• Dividend Yield: N/A
• Average Volume (3M): 95.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: 56.52%
• EPS Growth: 75.22%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 25,440,407
• 10 Day Avg. Volume: 116,541
• 30 Day Avg. Volume: 95,045
• PEG Ratio: 0.05
• Price to Book (P/B): 4.46
• Price to Sales (P/S): 62.24
• P/FCF Ratio: -16.56
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 13.77
• Enterprise Value/Gross Profit: 13.77
• Enterprise Value/Ebitda: -3.30
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.00 ▼(-52.38% Downside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is primarily held down by weak financial performance (tiny/volatile revenue, large losses, and poor cash generation) and a bearish technical setup (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend yield data, while the improved balance sheet is a modest positive.

Positive Factors

Strengthened balance sheet

Material improvement in leverage and higher equity provide durable financial runway for clinical programs and reduce near-term insolvency risk. Lower leverage improves optionality for partnerships or milestone financings and lessens pressure to aggressively cut R&D spending while trials progress.

Very high gross margins

Near-100% gross margins indicate low direct costs on current revenue streams, so any sustained commercial or licensing revenue would largely drop to the operating line. This structural margin profile supports scalable profitability once fixed operating costs and R&D are covered or reduced.

Proprietary clinical-stage pipeline

A proprietary clinical pipeline is a durable strategic asset: successful trial outcomes can create significant value, enable partnerships, and trigger milestone-based non-dilutive funding. The R&D focus aligns with long-term value creation even if near-term revenues remain minimal.

Negative Factors

Persistent negative cash flow

The company has not demonstrated consistent internal cash generation, forcing reliance on external funding. Over a 2–6 month horizon this elevates financing risk, can delay or scale back trials if capital is scarce, and increases probability of dilutive financing or onerous deal terms.

Deep ongoing losses and tiny, volatile revenue

Large losses relative to a tiny and inconsistent revenue base show the business lacks operational leverage and sustainable income. This structural profitability gap means value hinges on binary R&D outcomes and prolongs the timeline to self-funding, raising long-term execution risk.

Reliance on external capital

Dependence on capital markets or partners to fund operations creates exposure to market conditions and potential dilution. Even with an improved balance sheet, persistent burn makes financing a recurring structural risk that can constrain strategy and increase cost of capital over time.

ABVC BioPharma Business Overview & Revenue Model

Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

How the Company Makes Money

null

ABVC BioPharma Financial Statement Overview

Summary

Overall fundamentals are weak: very small and volatile revenue, deep ongoing losses (2025 net margin ~-739%), and a history of negative operating/free cash flow. The main offset is a strengthened 2025 balance sheet with materially improved leverage (debt-to-equity ~0.31) and higher equity, but profitability and cash generation remain the key risks.

Income Statement

Revenue remains very small and volatile, with 2025 revenue down ~25% year over year after a sharp rebound in 2024. Profitability is weak: the company is deeply loss-making across the period, with 2025 net loss of ~$5.9M on ~$0.8M of revenue (net margin ~-739%). A key positive is that gross profit is strong in 2024–2025 (near 100% gross margin), but operating expenses overwhelm the revenue base, keeping operating results meaningfully negative.

Balance Sheet

Leverage improved materially in 2025 as debt stayed moderate (~$3.5M) while equity rose to ~$11.1M, bringing debt-to-equity down to ~0.31 (from ~2.61 in 2024). Total assets increased to ~$21.1M, suggesting a stronger balance sheet versus prior years. The main weakness is ongoing losses, reflected in negative returns on equity (about -53% in 2025), which can pressure equity over time if losses persist.

Cash Flow

Cash generation is a major concern. In 2025, operating cash flow and free cash flow are reported at $0, following multiple years of meaningfully negative operating and free cash flow (e.g., roughly -$1.8M in 2024 and -$4.2M in 2023). Overall, the business has not demonstrated consistent ability to fund operations through internally generated cash, implying reliance on external capital and creating higher financing risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Mar 2022
Income Statement
Total Revenue	795.95K	509.59K	152.43K	969.78K	355.80K
Gross Profit	795.95K	508.83K	-149.61K	683.37K	350.71K
EBITDA	-6.65M	-4.34M	-6.33M	-15.20M	-10.97M
Net Income	-7.91M	-4.90M	-7.79M	-16.42M	-12.84M
Balance Sheet
Total Assets	21.06M	7.54M	7.78M	10.93M	13.70M
Cash, Cash Equivalents and Short-Term Investments	745.83K	928.55K	796.09K	1.47M	5.94M
Total Debt	3.47M	3.20M	2.77M	3.41M	3.34M
Total Liabilities	7.76M	6.82M	6.53M	6.34M	4.83M
Stockholders Equity	11.11M	1.23M	1.55M	4.45M	8.84M
Cash Flow
Free Cash Flow	-2.99M	-1.81M	-4.21M	-7.52M	-7.62M
Operating Cash Flow	-2.99M	-1.81M	-4.19M	-7.40M	-7.60M
Investing Cash Flow	-1.21M	0.00	-360.19K	-1.72M	-805.97K
Financing Cash Flow	4.64M	1.98M	3.87M	4.01M	10.00M

ABVC BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Negative. The current price of 2.1 is above the 20-day moving average (MA) of 1.44, above the 50-day MA of 1.78, and below the 200-day MA of 2.48, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 32.80 is Neutral, neither overbought nor oversold. The STOCH value of 29.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABVC.

ABVC BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JSPR	52 Neutral	$34.70M	-0.53	-191.12%	―	―	-24.38%
CAMP	52 Neutral	$284.52M	-2.32	-162.49%	―	―	5.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYFT	48 Neutral	$56.05M	-6.63	-63.13%	―	-17.94%	21.43%
INKT	48 Neutral	$42.81M	-5.39	―	―	―	21.48%
CRVO	45 Neutral	$39.91M	-2.65	-76.78%	―	-38.81%	-76.96%
ABVC	41 Neutral	$33.58M	-6.26	-88.89%	―	56.52%	75.22%